GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kymera Therapeutics KYMR · USD

Health Care · US listing · 🇺🇸 United States

Compare

138.86

+5.41%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$39.2m

FY2018FY2025

Net income

−$311.4m

FY2018FY2025

Free cash flow

−$234.3m

FY2018FY2025

Shareholders' equity

$1.58bn

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue$39.2m$47.1m$78.6m$46.8m$72.8m$34.0m$2.9m—
Gross profit$39.2m$47.1m$78.6m$46.8m$72.8m$34.0m$2.1m−$205,000
Research and development$316.6m$240.2m$189.1m$164.2m$137.0m$62.1m$37.2m$17.7m
Operating income−$349.4m−$261.6m−$165.5m−$161.3m−$100.5m−$46.3m−$42.2m−$21.5m
Net income−$311.4m−$223.9m−$147.0m−$154.8m−$100.2m−$45.6m−$41.3m−$21.5m
Diluted earnings per share-3.69-2.80-2.51-2.67-1.95-1.03-0.93-0.48

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets$1.74bn$978.0m$575.8m$603.1m$605.9m$487.2m$116.7m$44.2m
Cash and short-term investments$848.3m$488.7m$374.9m$407.2m$442.4m$296.2m$92.0m$41.3m
Total liabilities$163.1m$142.4m$180.8m$113.0m$146.3m$203.3m$191.1m$78.7m
Debt$13.8m$3.7m$2.6m$2.7m$2.3m$1.3m$1.8m$700,000
Shareholders' equity$1.58bn$835.6m$395.0m$490.2m$459.6m$283.9m−$74.4m−$34.4m
Shares outstanding84m80m59m58m51m44m45m45m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−$232.9m−$194.5m−$102.8m−$153.1m−$128.9m$88.1m$17.9m−$17.9m
Capital spending−$1.4m−$12.8m−$34.5m−$2.8m−$1.6m−$9.1m−$532,000−$1.4m
Free cash flow−$234.3m−$207.3m−$137.3m−$155.9m−$130.5m$79.0m$17.4m−$19.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$65.0m$34.4m$2.9m$2.8m$11.5m$22.1m$7.4m$3.7m
Gross profit$65.0m$34.4m$79.0m−$71.3m$9.4m$22.1m$7.4m$3.7m
Operating income−$75.6m−$84.2m−$97.9m−$92.5m−$84.6m−$74.4m−$80.8m−$72.1m
Net income−$61.2m−$69.2m−$87.0m−$82.2m−$76.6m−$65.6m−$70.8m−$62.5m
Diluted earnings per share-0.62-0.71-1.03-0.97-0.91-0.78-0.88-0.78
Cash from operations−$54.0m−$88.0m−$66.0m−$27.0m−$59.0m−$79.0m−$61.0m−$50.0m
Total assets$1.65bn$1.67bn$1.74bn$1.10bn$1.13bn$918.3m$978.0m$1.03bn
Cash and short-term investments$691.0m$650.9m$848.3m$505.7m$665.4m$463.1m$488.7m$550.0m
Debt$17.4m$13.7m$13.8m$13.7m$13.7m$13.2m$13.1m$12.9m
Shareholders' equity$1.51bn$1.54bn$1.58bn$946.3m$971.5m$786.2m$835.6m$892.9m

Financial ratios

Data as of 12 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%
Operating margin-794.3%-475.0%-186.7%-330.2%-137.4%-133.6%
Net margin-794.4%-475.6%-187.0%-330.6%-137.6%-134.0%
Return on equity-19.7%-26.8%-37.2%-31.6%-21.8%-16.1%
Return on assets-17.9%-22.9%-25.5%-25.7%-16.5%-9.4%
Free cash flow yield-2.4%-2.0%-1.0%-2.3%-2.2%1.9%
Revenue growth-16.7%-40.1%67.8%-35.7%114.0%1060.0%
Earnings growth39.1%52.3%-5.1%54.5%119.8%10.4%
Current ratio10.47x7.53x4.73x5.88x4.88x2.73x
Debt to equity0.01x0.02x0.02x0.01x0.01x0.01x
Equity ratio90.6%85.4%68.6%81.3%75.9%58.3%
Interest coverage-1250.50x-898.03x-748.81x-878.59x-571.67x-395.46x
R&D as a share of sales807.7%510.4%240.6%350.8%188.1%182.5%
Buybacks as a share of market value-5.5%-36.7%-1.1%-12.6%-15.6%0.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-5.8%2.9%—
Operating income29.4%49.8%—
Net income26.2%46.9%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin100.0%100.0%100.0%—
Operating margin-708.3%-443.0%-340.5%—
Net margin-620.4%-395.4%-308.5%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-21.1-14.4-10.1-9.3-32.6-60.5
Price to sales167.568.419.030.944.881.0

Market value over time

31 Aug 2020 to 9 Oct 2026, in USD

$63.8m$11.04bn

Share price return

Finished calendar years

202520242023202220212020
Return104%56%-5%-52%-27%124%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.